New drug SRN001 takes first step toward fighting lung scarring
Knowledge-focused
Recruiting now
This Phase 1 trial tests the safety and tolerability of an investigational drug called SRN001 in 30 healthy Korean and Caucasian men. Participants receive either SRN001 or a placebo to see how the drug moves through the body and whether it causes side effects. The goal is to gath…
Phase: PHASE1 • Sponsor: siRNAgen Therapeutics Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC